NZ631789A - Combination of direct acting antiviral agents and ribavirin for treating hcv patients - Google Patents

Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Info

Publication number
NZ631789A
NZ631789A NZ631789A NZ63178914A NZ631789A NZ 631789 A NZ631789 A NZ 631789A NZ 631789 A NZ631789 A NZ 631789A NZ 63178914 A NZ63178914 A NZ 63178914A NZ 631789 A NZ631789 A NZ 631789A
Authority
NZ
New Zealand
Prior art keywords
ribavirin
antiviral agents
direct acting
combination
acting antiviral
Prior art date
Application number
NZ631789A
Inventor
M Awni Walid
Rajeev M Menon
Tianli Wang
Wei Liu
Sandeep Dutta
Barry M Bernstein
L Campbell Andrew
Chih-Wei Lin
Thomas J Podsadecki
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from PCT/US2014/027556 external-priority patent/WO2014152635A1/en
Publication of NZ631789A publication Critical patent/NZ631789A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is the use of at least two direct acting antiviral agents (DAAs) and ribavirin for the manufacture of a medicament for the treatment of Hepatitis C virus (HCV) in an HCV patient, wherein said treatment does not include interferon, and wherein said at least two DAAs comprise: Compound 1 (glecaprevir) or a pharmaceutically acceptable salt thereof, and Compound 2 (Pibrentasvir) or a pharmaceutically acceptable salt thereof.
NZ631789A 2014-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients NZ631789A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461783437P 2014-03-14 2014-03-14
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Publications (1)

Publication Number Publication Date
NZ631789A true NZ631789A (en) 2018-01-26

Family

ID=61012481

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ631789A NZ631789A (en) 2014-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Country Status (1)

Country Link
NZ (1) NZ631789A (en)

Similar Documents

Publication Publication Date Title
NZ631155A (en) Combination of two antivirals for treating hepatitis c
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
MX2016012799A (en) Methods for treating hcv.
MX2015012536A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients.
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
MX2018005230A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon.
MX2017011488A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
JP2016513703A5 (en)
MX2018000240A (en) Methods for treating hcv.
MX2021014771A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
RU2015114543A (en) HEPATITIS TREATMENT METHODS
MX2021010145A (en) Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases.
MX2016012722A (en) Methods for treating hcv.
WO2016014527A3 (en) Stabilized nucleotides for medical treatment
PH12018502735A1 (en) Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof
PH12017500617A1 (en) Dosage regimen for pegylated interferon
RU2015114566A (en) HEPATITIS TREATMENT METHODS
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
MX2020001422A (en) Methods for treating hcv.
MX2018001905A (en) Methods for treating hcv.
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
MX2018000213A (en) Methods for treating hcv.
AU2019384793A8 (en) Methods for treating acute HCV
EA201491652A1 (en) MEANS FOR TREATING VIRAL HEPATITIS C

Legal Events

Date Code Title Description
PSEA Patent sealed
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 MAR 2021 BY SPRUSON + FERGUSON

Effective date: 20180531

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
LAPS Patent lapsed